法国赛诺菲的氨己烯酸在中国上市了吗？

France's Sanofi is used for the add-on treatment of epilepsy with partial seizures and secondary generalized seizures. It can also be used for infantile spasms and Lennox-Gastaut syndrome. 

Sanofi is the third largest pharmaceutical company in the world and first in Europe. Its business covers more than 100 countries around the world, and currently has approximately 11,000 scientists and 100,000 employees serving the health industry. Sanofi relies on its world-class research and development organization to develop innovative treatments and leads in seven therapeutic areas: cardiovascular disease, thrombosis, oncology, diabetes, central nervous system, internal medicine and vaccines.

Adverse reactions of using French Sanofi vigabatrin include:

1. Central nervous system:

(1) Nervous symptoms: can cause dizziness, fatigue, drowsiness, insomnia, ataxia, nervousness, distraction, Parkinson's disease, etc.

(2) Psychiatric symptoms: depression, prepsychotic symptoms (including conduct disorder, agitation, irritability and anxiety) and psychotic symptoms (including hallucinations, aggressive behavior and paranoia) can be seen.

2. Endocrine/metabolism: may cause weight gain.

3. Gastrointestinal tract: It can cause nausea, vomiting, upper abdominal pain, constipation and dry mouth.

4. Liver: There are case reports of liver failure.

5. Eyes: Double vision, abnormal color vision, visual field defects, retinal pigmentation, etc. may occur. There are also case reports of optic nerve shrinkage. More common in children.

6. Skin: Skin and facial flushing, rash, etc. may occur.

7. Others: Sudden discontinuation of medication may cause convulsive attacks.

Has French Sanofi's vigabatrin been launched in China?

It is understood that it has not yet been launched in China. Patients in need can always consult Medical Companion Travel for relevant matters!

Recommended related hot articles/newsDetail/91929.html